United Kingdom

People: Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

17 May 2019
Change (% chg)

$-1.97 (-3.09%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Childs, John 

Mr. John W. Childs serves as Director of the Company. Mr. Childs has been chairman and partner of J.W. Childs Associates, L.P., a private equity firm, since 1995. From 1991 to 1995, Mr. Childs was senior managing director of Thomas H. Lee Partners and from 1987 to 1990 was a managing director of Thomas H. Lee Partners. Prior to 1987, Mr. Childs was associated with the Prudential Insurance Company of America ("Prudential") for 17 years where he held various executive positions in the investment area, ultimately serving as senior managing director in charge of the Capital Markets Group at which time he was responsible for Prudential's approximately $77 billion fixed income portfolio, including all of the Capital Markets Group's investments in leveraged acquisitions. He is currently a director and chairman of the board of KB Wine Corporation, and serves as a director of KeyImpact Sales and Systems, Inc., Kleo Pharmaceuticals, Omax Health, J.W. Childs Asia Equities, This Realm, LLC, and SIMCOM, Inc. Mr. Childs holds a B.A. from Yale University and an M.B.A. from Columbia University. We believe that Mr. Childs' extensive operational and capital markets experience qualifies him to serve as a member of our Board.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 136,846
Long-Term Incentive Plans, USD --
All Other, USD 16,875
Fiscal Year Total, USD 153,721

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Declan Doogan


Vlad Coric


James Engelhart


Charles Conway


Kimberly Gentile


Robert Berman

As Of  31 Dec 2017